Old Web
English
Sign In
Acemap
>
authorDetail
>
Ibou Dieye
Ibou Dieye
Analysis Group
Medicine
Internal medicine
Oncology
Polatuzumab vedotin
Diffuse large B-cell lymphoma
4
Papers
0
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Factors associated with greater health-related quality of life benefits in people with hATTR amyloidosis with polyneuropathy treated with
2021
Journal of the Neurological Sciences
Duncan Brown
Montserrat Llonch
Chafic Karam
Min Yang
Nicolae Done
Ibou Dieye
Ana Bozas
James Signorovitch
Show All
Source
Cite
Save
Citations (0)
22 REAL-WORLD EFFECTIVENESS OF FIRST-LINE BIOLOGIC VEDOLIZUMAB IN CROHN'S DISEASE: ANALYSIS OF HIGHER TREATMENT EFFECT SUBPOPULATION FROM THE EVOLVE STUDY
2021
Gastroenterology
Andres Yarur
Brian Bressler
Song Wang
Shashi Adsul
Pravin Kamble
Michelle Luo
Erin Cook
Gautam Sajeev
Ibou Dieye
Gerassimos J. Mantzaris
Show All
Source
Cite
Save
Citations (0)
Cost-Effectiveness of Polatuzumab Vedotin Plus Bendamustine-Rituximab for Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the United States
2020
Blood
Keith A. Betts
Federico Felizzi
Ibou Dieye
Jia Li
Mathias Schulz
Samuel J Hong
Anthony Masaquel
Show All
Source
Cite
Save
Citations (0)
US cost-effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma.
2020
Journal of Comparative Effectiveness Research
Keith A. Betts
Per-Olof Thuresson
Federico Felizzi
Ella X. Du
Ibou Dieye
Jia Li
Mathias Schulz
Anthony Masaquel
Show All
Source
Cite
Save
Citations (0)
1